News for #Media and #Investors: Today we announced, in collaboration with ViiV Healthcare, our specialist HIV company, the presentation of 60 abstracts to showcase advances across our industry-leading infectious disease pipeline and portfolio at #IDWeek2024. 🔗 Learn more: https://gsk.to/3Y0Y3Gz
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brentford, Middlesex
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
We’re excited to be attending #CHEST2024 where we’re engaging with thought leaders and experts in pulmonary health. With approximately 177,000 US adults 65 years and older hospitalised due to RSV infection each year, it is important that we unite our efforts to get ahead of this virus, together.
-
#News for #Investors and #Media: Today we shared data at #CHEST2024 on one of our vaccines. Learn more: https://gsk.to/3Nfcq50
-
Around 1 in 5 invasive meningococcal disease (IMD) survivors are left with severe long-term after-effects, such as permanent physical disabilities. Survivors like Rodolpho. Now an amputee, paralympic equestrian champion Rodolpho shares his powerful story to warn others of the dangers of IMD. As we close #WorldMeningitisDay for another year, his testimony serves as our inspiration as we harness science and technology to work towards a meningococcal-free world by 2030. Find out more about Rodolpho’s story here: https://gsk.me/3TYJySl #DefeatMeningitis
-
News for #Media and #Investors from our specialist HIV company, ViiV Healthcare, on their commitment to increasing access to #HIV PrEP in low- and middle-income countries and Sub-Saharan Africa. Find out more: https://www.gsk.com/en-gb/
-
-
Invasive meningococcal disease (IMD) is a devastating disease caused by the bacteria Neisseria meningitidis, and affects around 1.2 million people around the world, each year. Among those who contract IMD, 1 in 6 will die, sometimes in as little as 24 hours. At GSK, we are committed to working towards a meningococcal-free world by finding solutions through our science and technology. As we close #WorldMeningitisDay for another year, take a moment to learn more about this disease 👇 #DefeatMeningitis
-
We’re incredibly proud that our CEO Emma Walmsley, has been named to Fortune Magazine's list of the 100 most powerful women, alongside other accomplished leaders in the Fortune 500 and Global 500.
-
-
We are honoured to have supported the 2024 #WellChildAwards yesterday, recognising inspirational young people, their carers and healthcare professionals. Congratulations to all of the winners for their courageousness and determination. Find out how together with community partners we’re making a positive impact on the health of vulnerable and marginalised people. https://lnkd.in/eybmD2Fd #AheadTogether
Here are some of our favourite photos from the #WellChildAwards, in association with GSK. Our winners have been truly celebrated, meeting celebrities such as KSI, Sir Rod Stewart, Kate Garraway, Beverley Knight, Pixie Lott, Oti Mabuse, as well as WellChild Patron Prince Harry, The Duke of Sussex. The event doesn't end here though. Keep an eye on our social media channels all week as we continue the celebrations, sharing our winners' stories and some of the highlights of the event.
-
-
It’s been a busy week at the 79th United Nations General Assembly (UNGA) and New York Climate Week! Heads of state, community leaders and representatives from industry are amongst those that have come together with a collective determination and commitment to tackle antimicrobial resistance (AMR). AMR is one of the most significant threats to health globally and without meaningful action by 2050, almost 40 million lives will have been lost. And, shockingly, as a result of AMR, life expectancy globally could be reduced by nearly 2 years. That’s why this week, we’ve championed the importance of innovation, sustainable access to appropriate antibiotics, responsible manufacturing and prevention measures to stop infections in the first place. But it’s also clear that tackling AMR goes beyond what any one organisation can do; it requires a multi-sectorial approach and collaboration between governments, the private sector, healthcare professionals, researchers, and communities. By combining our efforts, we can get ahead of AMR together. #UNGA79 #AMR #Collaboration #Innovation Find out more: https://gsk.to/4gA0kBf